Answers are grounded in this paper and cite their sources.
Retinoblastoma is the most common primary intraocular malignancy in children. Intra-arterial chemotherapy improves local drug delivery and globe salvage, but repeated catheterization may damage ocular vessels. Intravenous chemotherapy (IVC) may cause systemic toxicity. This trial will test whether two initial intravenous cycles followed by two intra-arterial cycles preserve efficacy while reducing the burden of each treatment route. We will enroll 288 untreated children aged > 3 months and weighing > 5 kg with unilateral American Joint Committee on Cancer (AJCC) cT2N0M0 retinoblastoma in this multicenter, open-label, assessor-masked, randomized noninferiority trial. A central interactive web response system will assign participants 1:1 using variable block randomization stratified by center and cT2a/cT2b stage. The experimental group will receive two cycles of IVC followed by two cycles of intra-arterial chemotherapy (IAC). The control group will receive four cycles of IAC. Focal therapy is permitted. The primary outcome is 2-year progression-free globe salvage assessed over 24 months. The trial will evaluate whether sequential intravenous plus intra-arterial chemotherapy provides acceptable tumor control while limiting treatment-related harm and resource use in unilateral cT2 disease. The primary outcome is the 2-year progression-free globe salvage rate. Secondary outcomes are 2-year globe salvage, objective response, all-cause mortality, recurrence, intracranial metastasis, local and systemic toxicity, retention of measurable vision, and treatment cost. Chinese Clinical Trial Registry, ChiCTR2000036586; prospectively registered on 24 August 2020.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: